T1	Participants 39 103	disseminated small noncleaved-cell lymphoma and B-cell leukemia:
T2	Participants 106 135	Children's Cancer Group study
T3	Participants 233 377	patients with disseminated small noncleaved-cell lymphoma and B-cell leukemia who were treated in four successive Children's Cancer Group trials
T4	Participants 403 490	462 patients with disseminated disease, 49 (10.6%) had CNS disease at diagnosis (CNS+).